TYRA — Tyra Biosciences Inc · catalysts, narrative & risks

Overview (as of the reference date, 2026-10-31)

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company headquartered in Carlsbad, California, focused on Fibroblast Growth Factor Receptor (FGFR) biology [1][4]. It trades on the Nasdaq, carries a market capitalization of roughly $1.48B, and its shares were quoted around $21.07 (having fallen from a 52-week high of ~$40.65) [15]. The company's lead candidate is oral dabogratinib, described as a potential first-in-class selective FGFR3 inhibitor, developed through its proprietary SNÅP precision-medicine platform [1][16].

Key recent catalysts (approximately August–October 2026)